• 1. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966
• 2. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 3. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847
• 4. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 5. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Halobenzoic acids and derivatives

Introduction to (4-benzylpiperazin-1-yl)(4-fluorophenyl)methanone (CAS No. 289475-97-4)

(4-benzylpiperazin-1-yl)(4-fluorophenyl)methanone, identified by its CAS number 289475-97-4, is a significant compound in the realm of pharmaceutical chemistry and medicinal research. This molecule, featuring a benzylpiperazine moiety linked to a 4-fluorophenyl group through a methanone bridge, has garnered attention due to its potential applications in the development of novel therapeutic agents.

The structural characteristics of this compound make it a versatile scaffold for drug design. The presence of the piperazine ring enhances its solubility and bioavailability, while the fluorine atom in the phenyl ring improves metabolic stability and binding affinity. These features are particularly valuable in the design of small-molecule inhibitors targeting various biological pathways.

Recent advancements in computational chemistry and molecular modeling have enabled researchers to explore the pharmacokinetic properties of (4-benzylpiperazin-1-yl)(4-fluorophenyl)methanone more effectively. Studies have shown that this compound exhibits promising interactions with enzymes and receptors involved in neurological disorders, making it a potential candidate for further investigation.

In the context of neurological research, (4-benzylpiperazin-1-yl)(4-fluorophenyl)methanone has been studied for its potential role in modulating neurotransmitter systems. The benzylpiperazine moiety is known to interact with serotonin and dopamine receptors, which are crucial for regulating mood, cognition, and motor control. The addition of a fluorine atom enhances these interactions, potentially leading to more potent and selective therapeutic effects.

Moreover, the compound's structural framework allows for modifications that can fine-tune its pharmacological properties. Researchers have explored derivatives of (4-benzylpiperazin-1-yl)(4-fluorophenyl)methanone to optimize its solubility, bioavailability, and target specificity. These modifications have led to the discovery of several novel analogs with enhanced efficacy and reduced side effects.

The synthesis of (4-benzylpiperazin-1-yl)(4-fluorophenyl)methanone involves multi-step organic reactions that require precise control over reaction conditions. Advanced synthetic methodologies, such as palladium-catalyzed cross-coupling reactions, have been employed to achieve high yields and purity. These techniques are essential for producing sufficient quantities of the compound for preclinical and clinical studies.

Preclinical studies have demonstrated the potential therapeutic benefits of (4-benzylpiperazin-1-yl)(4-fluorophenyl)methanone in animal models of neurological disorders. These studies have revealed that the compound can modulate neurotransmitter release and receptor activity, leading to improvements in cognitive function and motor coordination. The results from these studies have laid the groundwork for further clinical trials in humans.

The pharmaceutical industry has shown interest in developing drugs based on scaffolds similar to (4-benzylpiperazin-1-yl)(4-fluorophenyl)methanone due to its unique structural features and promising pharmacological properties. Companies are investing in research to explore its potential applications in treating conditions such as depression, anxiety, and neurodegenerative diseases.

As our understanding of biological pathways continues to evolve, so does our ability to design molecules that interact with specific targets with high precision. (4-benzylpiperazin-1-yl)(4-fluorophenyl)methanone represents a prime example of how structural modifications can lead to the discovery of novel therapeutic agents. Its continued study holds promise for advancing our knowledge of drug design and development.

• 874942-08-2((3,5-Difluorophenyl)(1-piperazinyl)methanone)
• 102391-98-0((4-Fluorophenyl)(piperazin-1-yl)methanone)
• 10366-88-8(N,n-diethyl-4-fluorobenzamide)
• 333756-49-3(1-(1,1'-biphenyl-4-ylcarbonyl)-4-(4-fluorobenzoyl)piperazine)
• 88229-29-2(Benzamide, 4-fluoro-N,N-bis(phenylmethyl)-)
• 56708-46-4(1-[(4-fluorophenyl)carbonyl]-4-methylpiperazine hydrochloride)
• 179334-10-2(1-(3-fluorobenzoyl)piperazine)
• 62748-48-5(Benzamide, 4-fluoro-N-[2-[methyl(phenylmethyl)amino]ethyl]-,hydrochloride)
• 423735-79-9(1-(4-fluorobenzoyl)-4-(1-naphthoyl)piperazine)
• 923237-42-7(1-(3,4-difluorobenzoyl)piperazine)